Show
Sort by
-
Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient‐reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS‐24 and SINUS‐52 studies
-
- Journal Article
- A1
- open access
Chemokine expression-based endotype clustering of chronic rhinosinusitis
-
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE) : a randomised, double-blind, placebo-controlled, phase 3 trial
-
A responder analysis to demonstrate Dupilumab treatment effect across objective and patient-reported subjective endpoints for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP)
(2021) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 147(2). p.AB132-AB132 -
COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab
-
Glukokortikoide und Covid-19
-
The GALEN rhinosinusitis cohort : chronic rhinosinusitis with nasal polyps affects health-related quality of life
-
- Journal Article
- A1
- open access
The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort : a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps
-
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
-
Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps : results from the randomized phase 3 sinus-24 study